Hanford Pharmaceuticals has completed the sale of its Cephalosporin manufacturing facility in Syracuse, NY, on September 24, 2009. As part of the deal, Hanford will continue to manufacture mastitis products in the facility.
As per the company, it is now better positioned not only to meet increased sales demand for its core business products, but also to expand into new areas outside of its current market space.
The company has also acquired a 84,000 square-foot facility and is currently developing the space for manufacturing, warehousing and laboratory support services. This facility will include both aseptic processing capability as well as space that can be used for non-sterile product manufacturing.
Additionally, the facility will provide the space necessary to increase Hanford’s ability to offer its broad range of contract pharmaceutical support services, including Validation Services, Analytical Methods Development, Regulatory and Document Support, Quality Control Testing and OSHA/FDA Required Safety and GMP Training, to name just a few.
Hanford’s contract manufacturing ramp-up calls for the installation of an aseptic filling and packaging line capable of lot sizes of up to 100,000 units, which will be able to handle vial sizes of 2-100ml. The facility is said to have sufficient space to accommodate multiple production installations with both clinical and commercial-scale output capabilities.